

Clinical Trial Protocol

Iranian Registry of Clinical Trials

08 Jul 2026

The effects of vitamin B12 supplementation in patients with diabetic peripheral neuropathy and low serum vitamin b12

Protocol summary

Study aim

The effects of vitamin B12 supplementation in diabetic peripheral neuropathy

Design

A total of 40 participants will be recruited and randomly assigned to 2 groups with a 1:1 allocation ratio. Random assignment will be done via block randomization.

Settings and conduct

Patients will be prescreened by telephone or face-to-face interview at 1 clinical of diabetes in Endocrinology and Metabolism Research Center (Tehran University of Medical Sciences, Tehran, Iran). All of investigators and patients involve will be masked to the treatments assignments until the study will be completed.

Participants/Inclusion and exclusion criteria

To be eligible for the study, patients will be satisfy the following criteria: male or female patients between 30 and 70 years of age, a MNSI 2 or higher, abnormal NCS, normal folate levels and low vitamin B12 levels. The main exclusion criteria from the study will be as follows: uncontrolled diabetes (HbA1c>9%), history of alcohol abuse, current smoker, current pregnancy or lactating women, diabetic foot , mental disease, heart failure, cancer, evidence of liver disease, impaired renal (GFR < 30)

Intervention groups

The patients will be received 1 capsule of 1000 mcg of vitamin B12 or 2 capsule of identical-looking two times daily for 4 months.

Main outcome variables

The primary endpoint was patient-reported neuropathy screening instrument (MNSI), and Neuropathy disability score (NDS) changes at 4 months.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210925052566N3**

Registration date: **2024-01-31, 1402/11/11**

Registration timing: **prospective**

Last update: **2024-01-31, 1402/11/11**

Update count: **0**

Registration date

2024-01-31, 1402/11/11

Registrant information

Name

Sayed Mahmoud Sajjadi Jazi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 8822 0038

Email address

m_sajadi@tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2024-02-29, 1402/12/10

Expected recruitment end date

2024-07-31, 1403/05/10

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The effects of vitamin B12 supplementation in patients with diabetic peripheral neuropathy and low serum vitamin b12

Public title

vitamin B12 supplementation in patients with diabetic peripheral neuropathy

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Patients will eligible for recruitment with a MNSI of 2 or higher, abnormal NCS results age 30-70 years old low levels of vitamin B12

Exclusion criteria:

current pregnancy or lactating women, alcohol intake, current smoker, diabetic foot mental disease, heart failure, cancer evidence of liver disease (such as viral hepatitis, autoimmune hepatitis, etc.) impaired renal (GFR < 30) (HbA1c>9%)

Age

From **30 years** old to **70 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Outcome assessor

Sample size

Target sample size: **40**

Randomization (investigator's opinion)

Randomized

Randomization description

50 patients with liver fibrosis, who have inclusion criteria and do not have exclusion criteria, based on a pre-designed random list (the list will be designed through the website

<https://www.sealedenvelope.com/simple-randomiser/v1/lists>) will be randomly assigned to two groups to receive vitamin b12 (1000 mcg/d or 2000 mcg/d). Each drug package is assigned a code, the codes will be A and B. To reduce the bias in placing people in the treatment or placebo groups, patients will be randomly assigned to one of the two groups using the blocked randomization method (the size of the blocks is 2).

Blinding (investigator's opinion)

Double blinded

Blinding description

In this study, blinding will be done in the type of supplements for researchers and patients. In this way, the appearance of the capsules will be the same and their packaging will be the same. Coding (codes will be A and B) will be done by someone outside the study.

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Research Ethics Committees of Endocrine & Metabolism Research Institute - Tehran University of Medic

Street address

Shariati Hospital, Kargar Shomali Ave.

City

Tehran

Province

Tehran

Postal code

1411713135

Approval date

2023-07-31, 1402/05/09

Ethics committee reference number

IR.TUMS.EMRI.REC.1402.041

Health conditions studied

1

Description of health condition studied

diabetic peripheral neuropathy

ICD-10 code

E11.4

ICD-10 code description

Type 2 diabetes mellitus with neurological complications

Primary outcomes

1

Description

Michigan neuropathy screening instrument (MNSI)

Timepoint

Baseline and 16 weeks

Method of measurement

Using standard scoring systems and questionnaires. Scoring is: Michigan neuropathy screening instrument , (0-10)

2

Description

Neuropathy disability score (NDS)

Timepoint

Baseline and 16 weeks

Method of measurement

Using standard scoring systems and questionnaires. Scoring is: Neuropathy disability score (0-10)

3

Description

Pain score

Timepoint

Baseline and 16 weeks

Method of measurement

Patients will be asked to score pain on a visual analog scale 0-10 with 10 being the worst pain ever

4**Description**

Fasting glucose and HBA1c

Timepoint

Baseline and 16 weeks

Method of measurement

lab kit

5**Description**

lipid profiles (HDL-c, LDL-c, TG, TC)

Timepoint

Baseline and 16 weeks

Method of measurement

lab kit

Secondary outcomes

empty

Intervention groups**1****Description**

Intervention group: vitamin B12 500 mcg EuRovital (twice a day),The patients will be received 1 tablet of 500 mcg of vitamin B12 two times daily for 4 months.

Category

Treatment - Drugs

2**Description**

Intervention group: vitamin B12 1000 mcg EuRovital (twice a day),The patients will be received 2 tablet of 500 mcg of vitamin B12 two times daily for 4 months.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

clinical of diabetes in Endocrinology and Metabolism Research Center (Tehran University of Medical

Full name of responsible person

Asieh Mansour

Street address

Shariati Hospital, Kargar Shomali Ave.

City

Tehran

Province

Tehran

Postal code

1411713135

Phone

+98 21 8822 0071

Email

asiehmansour@yahoo.com

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

Dr. Ali Akbari Sari

Street address

Shariati Hospital, Kargar Shomali Ave.

City

Tehran

Province

Tehran

Postal code

1411713135

Phone

+98 21 8822 0071

Email

asiehmansour@yahoo.com

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Tehran University of Medical Sciences

Full name of responsible person

Asieh Mansour

Position

asisstance professor

Latest degree

Ph.D.

Other areas of specialty/work

Nutrition

Street address

Shariati Hospital, Kargar Shomali Ave.

City

Tehran
Province
Tehran
Postal code
1411713135
Phone
+98 21 8822 0071
Email
asiehmansour@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Sayed Mamood Sajjadi -jazi
Position
associate professor
Latest degree
Subspecialist
Other areas of specialty/work
Internal Medicine
Street address
Shariati Hospital, Kargar Shomali, Tehran
City
Tehran
Province
Tehran
Postal code
1411713135
Phone
+98 21 8490 1000
Email
mahmood.sajadi@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Asieh Mansour
Position
assistant professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition

Street address
Shariati Hospital- Kargar shomali Ave, Tehran
City
Tehran
Province
Tehran
Postal code
1411713135
Phone
+98 21 8822 0071
Email
asiehmansour@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

Not applicable

Title and more details about the data/document

Data collected for the primary and secondary outcomes will be shared.

When the data will become available and for how long

Access starting 6 months after publication

To whom data/document is available

The data will only be available for people working in academic institutions.

Under which criteria data/document could be used

The data of the present study will only be accessible by for conducting Meta-analysis.

From where data/document is obtainable

To access the required data, the researchers can contact Dr. Sayed Mahmoud Sajjadi Jazi: email address: mahmood.sajadi@gmail.com

What processes are involved for a request to access data/document

The request will be assessed by the our group, and if all of us agree to the request, the requested data will be emailed.

Comments